AR064524A1 - Derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de tipo trpv1. - Google Patents
Derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de tipo trpv1.Info
- Publication number
- AR064524A1 AR064524A1 ARP070105891A ARP070105891A AR064524A1 AR 064524 A1 AR064524 A1 AR 064524A1 AR P070105891 A ARP070105891 A AR P070105891A AR P070105891 A ARP070105891 A AR P070105891A AR 064524 A1 AR064524 A1 AR 064524A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkylene
- aryl
- group
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
Abstract
Procedimiento de preparacion y aplicacion en terapéutica contra enfermedades mediadas por los receptores de tipo TRPV1. Reivindicacion 1: Un compuesto que responde a la formula (1) en la que el nucleo de pirrolopiridina es un grupo pirrolo[3,2- b]piridina, un grupo pirrolo[3,2- c]piridina, un grupo pirrolo[2,3-c)piridina o un grupo pirrolo[2,3-b]piridina; estando el nucleo de pirrolopiridina eventualmente sustituido en los carbonos de posicion 4, 5, 6 y/o 7 con uno o varios sustituyentes X, idénticos o diferentes uno de otro, elegidos entre un átomo de hidrogeno o de halogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquileno C1-6-O-, fluoroalcoxilo C1-6, ciano, tioalquilo C1-6, -S(O)-alquilo C1-6, -S(O)2alquilo C1-6, SF5, C(O)NR1R2, SO2NR1R2, nitro, NR1R2, OCONR1R2, NR3COR4, NR3CONR1R2, NR3SO2R5, NR3SO2NR1R2, aril-alquileno C1-6, heteroaril-alquileno C1-6, arilo o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; n es igual a 0, 1, 2 o 3; Y representa un arilo o un heteroarilo, estando el arilo o el heteroarilo eventualmente sustituidos con uno o varios grupos elegidos entre un átomo de halogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, hidroxilo, alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquileno C1-6-O-, fluoroalcoxilo C1-6, ciano, tioalquilo C1-6, tiol, -S(O)-alquilo C1-6, -S(O)2-alquilo C1-6, C(O)NR1R2, SO2NR1R2, SF5, nitro, OCONR1R2, NR3COR4, NR3CONR1R2, NR1R2, NR3SO2NR1R2, NR3COR4, NR3SO2R5, aril-alquileno C1-6, o arilo, estando el arilo y el aril-alquileno C1-6 eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; Z1, Z2, Z3, Z4 representan, independientemente uno de otro, un átomo de nitrogeno o un grupo C(R6), correspondiendo uno al menos a un átomo de nitrogeno y correspondiendo uno al menos a un grupo C(R6); estando el átomo de nitrogeno o uno de los átomos de nitrogeno presentes en el ciclo, definido como nitrogeno de posicion 1, eventualmente sustituido con R7 cuando el átomo de carbono en posicion 2 o 4 con respecto a este nitrogeno de referencia está sustituido con un grupo oxo o tio; Z representa o bien una amina cíclica unida por el átomo de nitrogeno, de la formula (2) en la que A representa un grupo alquileno C1-7 eventualmente sustituido con uno o dos grupos R8; B representa un grupo alquileno C1-7 eventualmente sustituido con uno o dos grupos R9; L representa un enlace, un átomo de azufre, de oxígeno o de nitrogeno; estando el átomo de nitrogeno eventualmente sustituido con un grupo R10 o R11; estando los átomos de carbono de la amina cíclica Z eventualmente sustituidos con uno o varios grupos R12 idénticos o diferentes uno de otro; o bien una amina acílica, unida por el átomo de nitrogeno, de la formula NRaRb en la que Ra y Rb representan, independientemente uno de otro, un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, hidroxilo, alcoxilo C1-6, cicloalquil C3-7-alquileno C1-6-O-, fluoroalcoxilo C1-6, alquil C1-6-C(O)-, HO-C(O)-alquileno C1-6, alquil C1-6-O-C(O)-alquileno C1-6, arilo o heteroarilo, pudiendo estar Ra y Rb eventualmente sustituidos con uno o varios grupos Rc idénticos o diferentes uno de otro; Rc representa un átomo de halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, cicloalquil C3-7- alquileno C1-6-O-, fluoroalcoxilo C1-6, tioalquilo C1-6, -S(O)-alquilo C1-6, -S(O)2-alquilo C1-6, ciano, C(O)NR1R2, NR1R2, SO2NR1R2, NR3COR4, NR3SO2R5, OC(O)NR1R2, NR3COOR5, NR3CONR1R2, NR3SO2NR1R2, hidroxilo, tiol, oxo, tio, aril-alquileno C1-6, arilo o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; R1 y R2 representan, independientemente uno de otro, un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, aril-alquileno C1-6, arilo o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; o R1 y R2 forman conjuntamente, con el átomo de nitrogeno que les lleva, un grupo azetidinilo, pirrolidinilo, piperidinilo, azepinilo, morfolinilo, tiomorfolinilo, piperazinilo, homopiperazinilo, estando este grupo eventualmente sustituido con un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, aril-alquileno C1-6, arilo o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; R3 y R4 representan, independientemente uno de otro, un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, aril- alquileno C1-6, arilo o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1- 6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; o R3 y R4 forman conjuntamente un grupo alquileno C2-6; o R1 y R3 forman conjuntamente un grupo alquileno C2-5; R5 representa un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, aril-alquileno C1-6, arilo o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; o R3 y R5 forman conjuntamente un grupo alquileno C2-5; R6 representa un átomo de hidrogeno o de halogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquileno C1-6-O-, fluoroalcoxilo C1-6, tioalquilo C1-6, -S(O)alquilo C1-6, -S(O)2-alquilo C1-6, hidroxilo, tiol, oxo, tio, arilo, aril-alquileno C1-6, heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; R7 representa un átomo de hidrogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquileno C1-6-O-, fluoroalcoxilo C1-6, arilo, aril-alquileno C1-6 o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; R8, R9 y R10 se definen de tal manera que: dos grupos R8 pueden formar conjuntamente un enlace o un grupo alquileno C1-6; dos grupos R9 pueden formar conjuntamente un enlace o un grupo alquileno C1- 6; R8 y R9 pueden formar conjuntamente un enlace o un grupo alquileno C1-6; R8 y R10 pueden formar conjuntamente un enlace o un grupo alquileno C1-6; R9 y R10 pueden formar conjuntamente un enlace o un grupo alquileno C1-6; R11 representa un átomo de hidrogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquileno C1-6-O-, fluoroalcoxilo C1-6, hidroxilo, alquil C1-6-CO-, COOR5, C(O)NR1R2, aril-alquileno C1-6, arilo o heteroarilo, estando el arilo y el heteroarilo eventualmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, cicloalcoxilo C3-7, fluoroalcoxilo C1-6, nitro o ciano; R12 representa un átomo de fluor, un grupo alquilo C1-6 eventualmente sustituido con un grupo R13, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, cicloalquil C1-6-1,1-diilo, heterocicloalquil C3-7-1,1-diilo eventualmente sustituido sobre un átomo de nitrogeno con un grupo R11, alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquileno C1-6-O-, fluoroalcoxilo C1-6, CO2H, C(O)O-alquilo C1-6, C(O)NR1R2, NR1R2, NR3COR4, OC(O)NR1R2, NR3COOR5, NR3CONR1R2, hidroxilo, tiol, oxo, tio, aril-alquileno C1-6, arilo, estando el arilo eventualmente sustituido con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-6, fluoroalquilo C1-6, alcoxilo C1-6, cicloalcoxilo C3-7, fluoroalcoxilo C1-6, nitro o ciano; R13 representa un grupo alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquileno C1-6-O-, C(O)NR1R2, NR1R2, NR3COR4, OC(O)NR1R2, NR3COOR5, hidroxilo; pudiendo estar el o los átomos de nitrogeno del compuesto de la formula general (1) en forma oxidada; en el estado de base o de sal de adicion a un ácido, así como en el estado de hidrato o de solvato. Reivindicacion 11: Un procedimiento de preparacion de un compuesto de la formula (1) de acuerdo con una cualquiera d
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0611353A FR2910473B1 (fr) | 2006-12-26 | 2006-12-26 | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064524A1 true AR064524A1 (es) | 2009-04-08 |
Family
ID=38234895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105891A AR064524A1 (es) | 2006-12-26 | 2007-12-26 | Derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de tipo trpv1. |
Country Status (11)
Country | Link |
---|---|
US (3) | US8153650B2 (es) |
EP (1) | EP2125811B1 (es) |
JP (1) | JP5284274B2 (es) |
AR (1) | AR064524A1 (es) |
CL (1) | CL2007003826A1 (es) |
FR (1) | FR2910473B1 (es) |
PA (1) | PA8764301A1 (es) |
PE (1) | PE20081549A1 (es) |
TW (1) | TW200835486A (es) |
UY (1) | UY30842A1 (es) |
WO (1) | WO2008093024A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2910473B1 (fr) * | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
FR2926554B1 (fr) * | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
FR2926553B1 (fr) * | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
KR101939710B1 (ko) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
KR20210081451A (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
PT2981536T (pt) | 2013-04-03 | 2017-08-09 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida e sua utilização como medicamentos para o tratamento da hepatite b |
JP6441315B2 (ja) | 2013-05-17 | 2018-12-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
DK3060547T3 (en) | 2013-10-23 | 2018-01-15 | Janssen Sciences Ireland Uc | CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CA2936947A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
JP6845231B2 (ja) | 2015-09-29 | 2021-03-17 | ノヴィラ・セラピューティクス・インコーポレイテッド | B型肝炎抗ウイルス薬の結晶形態 |
JP2019511542A (ja) | 2016-04-15 | 2019-04-25 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合阻害剤を含む組み合わせ及び方法 |
WO2018132533A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
CA3071861A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
AU2020269897A1 (en) | 2019-05-06 | 2021-10-14 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL106957C (es) * | 1958-09-30 | |||
US6630496B1 (en) * | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
US6436965B1 (en) * | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
US6566367B2 (en) | 2000-12-12 | 2003-05-20 | Pfizer Inc. | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines |
DE10147672A1 (de) * | 2001-09-27 | 2003-04-10 | Bayer Ag | Substituierte 2,5-Diamidoindole und ihre Verwendung |
EP2033953A1 (en) | 2002-02-15 | 2009-03-11 | Glaxo Group Limited | Vanilloid receptor modulators |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
JP2004091480A (ja) * | 2002-07-11 | 2004-03-25 | Takeda Chem Ind Ltd | ピロロピリジン誘導体およびその用途 |
AU2003281044A1 (en) * | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Pyrrolopyridine derivative and use thereof |
PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
US20060183753A1 (en) * | 2002-12-20 | 2006-08-17 | Bayer Healthcare Ag | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
JP2006515334A (ja) | 2003-01-16 | 2006-05-25 | エスビー ファームコ プエルト リコ インコーポレーテッド | CRF受容体アンタゴニストとしてのヘテロアリール置換ピロロ[2,3−b]ピリジン誘導体 |
ATE450533T1 (de) | 2003-02-14 | 2009-12-15 | Glaxo Group Ltd | Carboxamidderivate |
AR045979A1 (es) | 2003-04-28 | 2005-11-23 | Astrazeneca Ab | Amidas heterociclicas |
WO2004108133A2 (en) | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
BRPI0411083A (pt) | 2003-06-12 | 2006-07-25 | Astellas Pharma Inc | derivado de benzamida ou sais do mesmo |
MXPA06003158A (es) | 2003-09-22 | 2006-06-05 | Pfizer | Derivados de triazol sustituidos como antagonistas de oxitocina. |
WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
CA2542494A1 (en) * | 2003-10-15 | 2005-05-06 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
WO2006040522A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinoline derivatives |
FR2888848B1 (fr) | 2005-07-22 | 2007-09-28 | Sanofi Aventis Sa | Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
EP1963313B1 (en) * | 2005-11-28 | 2012-11-14 | Madrigal Pharmaceuticals, Inc. | Inhibitors of diacylglycerol acyltransferase (dgat) |
FR2910473B1 (fr) * | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
US8440830B2 (en) * | 2007-09-19 | 2013-05-14 | 4Sc Ag | Tetrahydro-fused pyridines as histone deacetylase inhibitors |
-
2006
- 2006-12-26 FR FR0611353A patent/FR2910473B1/fr not_active Expired - Fee Related
-
2007
- 2007-12-20 EP EP07872409.3A patent/EP2125811B1/fr active Active
- 2007-12-20 WO PCT/FR2007/002122 patent/WO2008093024A2/fr active Application Filing
- 2007-12-20 JP JP2009543495A patent/JP5284274B2/ja not_active Expired - Fee Related
- 2007-12-25 TW TW096150025A patent/TW200835486A/zh unknown
- 2007-12-26 CL CL2007003826A patent/CL2007003826A1/es unknown
- 2007-12-26 UY UY30842A patent/UY30842A1/es unknown
- 2007-12-26 PA PA20078764301A patent/PA8764301A1/es unknown
- 2007-12-26 AR ARP070105891A patent/AR064524A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000037A patent/PE20081549A1/es not_active Application Discontinuation
-
2009
- 2009-06-23 US US12/489,672 patent/US8153650B2/en not_active Expired - Fee Related
-
2012
- 2012-02-10 US US13/370,940 patent/US8716272B2/en not_active Expired - Fee Related
- 2012-02-10 US US13/370,956 patent/US8716273B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5284274B2 (ja) | 2013-09-11 |
FR2910473A1 (fr) | 2008-06-27 |
US20120142669A1 (en) | 2012-06-07 |
CL2007003826A1 (es) | 2009-01-23 |
JP2010514742A (ja) | 2010-05-06 |
EP2125811B1 (fr) | 2013-05-29 |
UY30842A1 (es) | 2008-07-31 |
US20100041634A1 (en) | 2010-02-18 |
WO2008093024A2 (fr) | 2008-08-07 |
PE20081549A1 (es) | 2008-12-14 |
US8716273B2 (en) | 2014-05-06 |
EP2125811A2 (fr) | 2009-12-02 |
TW200835486A (en) | 2008-09-01 |
US8716272B2 (en) | 2014-05-06 |
US20120142670A1 (en) | 2012-06-07 |
FR2910473B1 (fr) | 2009-02-13 |
PA8764301A1 (es) | 2008-11-19 |
WO2008093024A3 (fr) | 2008-10-02 |
US8153650B2 (en) | 2012-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064524A1 (es) | Derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de tipo trpv1. | |
AR061946A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y composiciones farmaceuticas | |
AR070214A1 (es) | Derivados de indol-2-carboxamida y de azaindol-2-carboxamida sustituidas con un grupo silanilo, su preparacion y su aplicacion en terapeutica | |
AR062897A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion, composicion farmaceutica que los comprende y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores not. | |
AR062143A1 (es) | Derivados de n-(amino- heteroaril)-1h-indol-2-carboxamidas y un procedimiento de preparacion | |
AR070207A1 (es) | Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica | |
AR057668A1 (es) | Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparacion, composiciones farmaceuticas y su aplicacion en terapeutica | |
AR064937A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica | |
AR070206A1 (es) | Derivados de carboxamidas azabiciclicas su preparacion y su aplicacion en terapeutica | |
CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
AR070208A1 (es) | Derivados de carboxamidas n- azabiciclicas su preparacion y su aplicacion en terapeutica | |
NO20065184L (no) | 1-amino-ftalazinderivater, deres fremstilling og terapeutiske anvendelse derav | |
AR070995A1 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe | |
AR054857A1 (es) | Derivados de n- (heteroaril)-1- heteroarilquil-1 h - indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica | |
BRPI1011683B8 (pt) | derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos | |
AR059339A1 (es) | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene | |
BRPI0607589A2 (pt) | derivados de imidazo [1,5-a] piridinas, o respectivo processo de preparo e as composições farmacêuticas que os contêm | |
CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
ECSP077215A (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
AR038404A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye | |
AR066954A1 (es) | Derivados de 7- alquinil-1,8- naftiridonas , su preparacion y su aplicacion en terapeutica | |
AR044906A1 (es) | Derivados de difenilpiridina, su preparacion y su aplicacion en terapeutica | |
AR075614A1 (es) | Piperidinas 1, 4-disustituidas, una composicion farmaceutica que las comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por los receptores v1a de vasopresina. | |
AR057975A1 (es) | DERIVADOS DE QUINAZOLINAS, PROCESO DE OBTENCIoN Y COMPOSICIONES FARMACEUTICAS. | |
BRPI0509564A (pt) | derivados pirrolo(2,3-b)piridina, respectivo preparo e respectiva utilização farmacêutica como inibidores de quinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |